Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 9

Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature

Pages
771–775
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, we aim to reviewthe current literature on this evolving topic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Liver transplantation is the main curative therapy for end-stage liver disease.
📊
Key Findings & Data:The high rate of sustained virologic response through DAA has brought newtreatment options for the patients during the pre- and post-transplantation periods.
💡
Conclusion & Impact:Thus, we aim to reviewthe current literature on this evolving topic.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally.However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list,which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and inrecent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have beentransplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought newtreatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to reviewthe current literature on this evolving topic.

🔖

Cite This Article

ÖRMECİ, A. Ç., YILDIZ, Ç., SABERI, B., GÜRAKAR, M., ŞİMŞEK, C., GÜRAKAR, A. (2019). Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 9, 771–775. https://ajindex.com/articles/409264

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Girlanda R, Deceased organ donation for transplantation: Challenges and opportunities. World J Transplant 2016
  2. [CrossRef] 2. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015
  3. [CrossRef] 3. Ciesek S, Proske V, Otto B, et al. Efficacy and safety of sofosbuvir/ ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis 2016
  4. [CrossRef] 4. Rudd RA. Increases in drug and opioid-involved overdose deaths-United States, 2010-2015. MMWR. Morbidity and mortality weekly report, 2016
  5. [CrossRef] 5. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995
  6. [CrossRef] 6. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002
  7. [CrossRef] 7. Humar A, Morris M, Blumberg E, et al., Nucleic acid testing (NAT) of organ donors: is the ‘best’test the right test? A consensus conference report. Am J Transplant 2010
  8. [CrossRef] 8. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL, Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999
  9. [CrossRef] 9. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006
  10. [CrossRef] 10. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant 2011
  11. [CrossRef] 11. Goldberg DS, Blumberg E, McCauley M, Abt P, Levine M. Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic. Am J Transplant 2016
  12. [CrossRef] 12. Sibulesky L, Javed I, Reyes JD, Limaye AP. Changing the paradigm of organ utilization from PHS increased-risk donors: an opportunity whose time has come? Clin Transplant 2015
  13. [CrossRef] 13. Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation. Hepatology 2018
  14. [CrossRef] 14. Hagan H, Pouge